Simple blood test could spot kidney patients at risk of failure

NCT ID NCT02199145

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at a new blood test that measures specific antibodies in people with membranous nephropathy, an autoimmune kidney disease. The test aims to predict which patients are more likely to develop kidney failure. Researchers will follow 52 adults over time to see if the test results match their actual kidney health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this test could help doctors identify which membranous nephropathy patients are at highest risk of kidney failure, allowing earlier and more targeted treatment.
What could go wrong: This is a small, early-stage study with only 52 participants. The test needs confirmation in larger, more diverse groups before it can be used in routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MEMBRANOUS NEPHROPATHY

Contacts and locations

Show contact details

Locations

AP-HM

Marseille, 13354, France
CHU de Besançon

Besançon, France
Nephrology Department, Nice University Hospital

Nice, 06003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.